Jefferies analyst, David Windley, reiterated his Buy rating on shares of PRA Health Sciences (NASDAQ: PRAH) after the company released ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE